Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 15, 2023, titled "Zydus receives final approval from the USFDA for Darunavir Tablets 600 mg and 800 mg, and tentative approval for 75 mg and 150 mg tablets".